FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1832681383> ?p ?o ?g. }

• W1832681383 endingPage "R46" @default.
• W1832681383 startingPage "R46" @default.
• W1832681383 abstract "Effectiveness of therapy with individual disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is limited, and the number of available DMARDs is finite. Therefore, at some stage during the lengthy course of RA, institution of traditional DMARDs that have previously been applied may have to be reconsidered. In the present study we investigated the effectiveness of re-employed methotrexate in patients with a history of previous methotrexate failure (original course). A total of 1,490 RA patients (80% female, 59% rheumatoid factor positive) were followed from their first presentation, yielding a total of 6,470 patient-years of observation. We identified patients in whom methotrexate was re-employed after at least one intermittent course of a different DMARD. We compared reasons for discontinuation, improvement in acute phase reactants, and cumulative retention rates of methotrexate therapy between the original course of methotrexate and its re-employment. Similar analyses were peformed for other DMARDs. Methotrexate was re-employed in 86 patients. Compared with the original courses, re-employment was associated with a reduced risk for treatment termination because of ineffectiveness (P = 0.02, by McNemar test), especially if the maximum methotrexate dose of the original course had been low (<12.5 mg/week; P = 0.02, by logistic regression). In a Cox regression model, re-employed MTX was associated with a significantly reduced hazard of treatment termination compared with the original course of methotrexate, adjusting for dose and year of employment (hazard ratio 0.64, 95% confidence interval 0.42-0.97; P = 0.04). These findings were not recapitulated in analyses of re-employment of other DMARDs. Re-employment of MTX despite prior inefficacy, but not re-employment of other DMARDs, is an effective therapeutic option, especially in those patients in whom the methotrexate dose of the original course was low." @default.
• W1832681383 created "2016-06-24" @default.
• W1832681383 creator A5012296122 @default.
• W1832681383 creator A5020718006 @default.
• W1832681383 creator A5060950932 @default.
• W1832681383 creator A5061411814 @default.
• W1832681383 creator A5070920613 @default.
• W1832681383 creator A5090753435 @default.
• W1832681383 date "2006-01-01" @default.
• W1832681383 modified "2023-10-16" @default.
• W1832681383 cites W125728277 @default.
• W1832681383 cites W189467709 @default.
• W1832681383 cites W1933099418 @default.
• W1832681383 cites W1937514324 @default.
• W1832681383 cites W1969821170 @default.
• W1832681383 cites W2006549880 @default.
• W1832681383 cites W2006697482 @default.
• W1832681383 cites W2010707109 @default.
• W1832681383 cites W2012198083 @default.
• W1832681383 cites W2023260615 @default.
• W1832681383 cites W2046533370 @default.
• W1832681383 cites W2053171941 @default.
• W1832681383 cites W2057760376 @default.
• W1832681383 cites W2064119537 @default.
• W1832681383 cites W2082583194 @default.
• W1832681383 cites W2098077764 @default.
• W1832681383 cites W2099559204 @default.
• W1832681383 cites W2105764923 @default.
• W1832681383 cites W2112755762 @default.
• W1832681383 cites W2113730861 @default.
• W1832681383 cites W2114270885 @default.
• W1832681383 cites W2120332428 @default.
• W1832681383 cites W2131237902 @default.
• W1832681383 cites W2134171514 @default.
• W1832681383 cites W2139876175 @default.
• W1832681383 cites W2149899765 @default.
• W1832681383 cites W2152348310 @default.
• W1832681383 cites W2169817209 @default.
• W1832681383 cites W2261130562 @default.
• W1832681383 cites W2265946565 @default.
• W1832681383 cites W2268787646 @default.
• W1832681383 cites W2331320446 @default.
• W1832681383 cites W2402241442 @default.
• W1832681383 cites W2412177641 @default.
• W1832681383 cites W2471354035 @default.
• W1832681383 cites W53352406 @default.
• W1832681383 cites W84416910 @default.
• W1832681383 cites W89611558 @default.
• W1832681383 doi "https://doi.org/10.1186/ar1902" @default.
• W1832681383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1526609" @default.
• W1832681383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16507172" @default.
• W1832681383 hasPublicationYear "2006" @default.
• W1832681383 type Work @default.
• W1832681383 sameAs 1832681383 @default.
• W1832681383 citedByCount "27" @default.
• W1832681383 countsByYear W18326813832012 @default.
• W1832681383 countsByYear W18326813832013 @default.
• W1832681383 countsByYear W18326813832014 @default.
• W1832681383 countsByYear W18326813832016 @default.
• W1832681383 countsByYear W18326813832017 @default.
• W1832681383 countsByYear W18326813832018 @default.
• W1832681383 countsByYear W18326813832019 @default.
• W1832681383 countsByYear W18326813832020 @default.
• W1832681383 countsByYear W18326813832021 @default.
• W1832681383 countsByYear W18326813832023 @default.
• W1832681383 crossrefType "journal-article" @default.
• W1832681383 hasAuthorship W1832681383A5012296122 @default.
• W1832681383 hasAuthorship W1832681383A5020718006 @default.
• W1832681383 hasAuthorship W1832681383A5060950932 @default.
• W1832681383 hasAuthorship W1832681383A5061411814 @default.
• W1832681383 hasAuthorship W1832681383A5070920613 @default.
• W1832681383 hasAuthorship W1832681383A5090753435 @default.
• W1832681383 hasBestOaLocation W18326813831 @default.
• W1832681383 hasConcept C105795698 @default.
• W1832681383 hasConcept C126322002 @default.
• W1832681383 hasConcept C141071460 @default.
• W1832681383 hasConcept C151956035 @default.
• W1832681383 hasConcept C186282968 @default.
• W1832681383 hasConcept C198451711 @default.
• W1832681383 hasConcept C207103383 @default.
• W1832681383 hasConcept C2777575956 @default.
• W1832681383 hasConcept C2778715236 @default.
• W1832681383 hasConcept C2781059491 @default.
• W1832681383 hasConcept C33923547 @default.
• W1832681383 hasConcept C44249647 @default.
• W1832681383 hasConcept C50382708 @default.
• W1832681383 hasConcept C71924100 @default.
• W1832681383 hasConceptScore W1832681383C105795698 @default.
• W1832681383 hasConceptScore W1832681383C126322002 @default.
• W1832681383 hasConceptScore W1832681383C141071460 @default.
• W1832681383 hasConceptScore W1832681383C151956035 @default.
• W1832681383 hasConceptScore W1832681383C186282968 @default.
• W1832681383 hasConceptScore W1832681383C198451711 @default.
• W1832681383 hasConceptScore W1832681383C207103383 @default.
• W1832681383 hasConceptScore W1832681383C2777575956 @default.
• W1832681383 hasConceptScore W1832681383C2778715236 @default.
• W1832681383 hasConceptScore W1832681383C2781059491 @default.
• W1832681383 hasConceptScore W1832681383C33923547 @default.

• next